Early asset assessment informing BD&L due diligence
![Early asset assessment informing BD&L due diligence Early asset assessment informing BD&L due diligence](/application/files/thumbnails/image_sm/6117/1432/0148/Early_Asset_Strategy_Case_4_1600x707.jpg)
Goal
The client had a BD&L opportunity for an asset being explored in ongoing phase 1/2a clinical trials for two rare diseases indications related to inherited blood disorders. In order to inform the BD&L decision, the disease background and current treatment options, future treatment and potential market impact, the epidemiology/ price potential and Market Access implications needed to be understood for the EU5 and the US.